Cost of Levothyroxine in 2026: Brand, Generic, Compounded, and Armour Thyroid Prices Explained

What Does Generic Levothyroxine Actually Cost in 2026?

Generic levothyroxine remains one of the least expensive chronic-disease medications available in the United States. At most large-chain pharmacies, a 30-day supply of 100 mcg tablets costs between $4 and $30 cash price, and GoodRx or similar coupon platforms routinely bring that figure to $4 to $9 at Kroger, Walmart, and Costco. Nearly every commercial insurance plan lists generic levothyroxine at Tier 1 (preferred generic), meaning the copay for insured patients is commonly $0 to $10 per month.

Levothyroxine is consistently among the top three most-dispensed prescriptions in the U.S. The FDA's Office of Generic Drugs notes that generic levothyroxine products meeting narrow therapeutic index (NTI) standards require bioequivalence testing within a tighter 90% confidence interval of 90.00% to 111.11% for AUC and Cmax, which is a stricter window than the standard 80% to 125% used for most generics [1]. That tighter standard is why the FDA approved a final rule in 2019 requiring all levothyroxine tablets to be approved drugs rather than grandfathered products.

Dose affects price only marginally for generics. A 30-day supply of 25 mcg and a 30-day supply of 200 mcg typically differ by no more than $2 to $4 cash at the same pharmacy. Splitting higher-dose tablets is sometimes suggested to reduce cost, but the American Thyroid Association's 2014 guidelines [2] caution against tablet-splitting for levothyroxine specifically, because the hormone content per milligram of tablet weight is not always uniform across the tablet face.

Key cash-price benchmarks (generic levothyroxine, 100 mcg, 30 tablets, 2026)

• Walmart $4 pharmacy program: approximately $4
• Costco pharmacy with GoodRx: approximately $5 to $7
• CVS without coupon: approximately $18 to $28
• Walgreens without coupon: approximately $20 to $30
• Independent pharmacy with GoodRx: approximately $8 to $15

Prices shift slightly by zip code; rural areas with fewer competing pharmacies may see the upper end of these ranges.

How Much Does Brand-Name Synthroid Cost?

Synthroid (levothyroxine sodium, AbbVie) carries a list price of roughly $300 to $450 for a 30-day supply in 2026, depending on dose strength. That number, however, is rarely what patients pay.

AbbVie's Synthroid Savings Card program offers eligible commercially insured patients a copay of as low as $0 per month, with a maximum benefit of roughly $150 per fill, subject to annual program caps and eligibility criteria [3]. Patients on Medicare or Medicaid do not qualify for manufacturer copay cards under federal anti-kickback rules, which is an important distinction. Without insurance and without a savings card, a patient paying full list price for Synthroid faces a cost roughly 10 to 30 times higher than the equivalent generic.

The clinical rationale for prescribing brand-name Synthroid over generic levothyroxine is debated. A 2017 study published in the journal Thyroid examined serum TSH variability across levothyroxine formulations and found no statistically significant difference in TSH stability between Synthroid and NTI-compliant generics in most patients [4]. The American Association of Clinical Endocrinology (AACE) and the American Thyroid Association (ATA) jointly stated in their 2012 hypothyroidism guidelines that "substitution of one L-thyroxine product for another should be done with caution and with retesting of TSH after 6 weeks" [2]. That guidance does not prohibit generic substitution; it recommends monitoring after any switch, regardless of direction.

Some prescribers write "Dispense As Written" (DAW) to prevent automatic generic substitution. This is appropriate for patients with documented TSH instability after a prior substitution, but not as a blanket preference. Patients who specify brand-name Synthroid without a copay card and without insurance should be aware of the sharp cost differential.

Tirosint: The Gel-Cap Formulation and Its Price Tag

Tirosint (levothyroxine sodium capsules, IBSA Pharma) is a gel-cap formulation containing only four ingredients: levothyroxine, gelatin, glycerin, and water. It is designed for patients who have demonstrated absorption problems with tablet formulations, such as those with celiac disease, atrophic gastritis, or those taking medications like calcium carbonate, proton pump inhibitors, or cholestyramine.

The list price for Tirosint in 2026 runs approximately $230 to $310 for a 30-day supply. IBSA offers the MyWay Savings Program, which can reduce out-of-pocket cost to $0 to $15 per fill for eligible commercially insured patients [5]. A liquid formulation, Tirosint-SOL, carries a similar price point and may be preferred for patients who have difficulty swallowing capsules, including children and elderly patients.

Insurance coverage for Tirosint requires prior authorization at most plans. Formulary placement is typically Tier 3 or non-preferred brand. Successfully obtaining PA usually requires documentation of failed trials on at least one generic tablet formulation plus a documented clinical reason for the liquid or gel-cap format, such as a confirmed absorption disorder or concurrent use of a known interfering medication.

Armour Thyroid Cost in 2026: What Patients Pay for Desiccated Thyroid Extract

Armour Thyroid (desiccated thyroid extract, or DTE, manufactured by AbbVie) is standardized to contain 38 mcg of T4 and 9 mcg of T3 per 60 mg grain. The cash price for a 30-day supply runs approximately $60 to $90 in 2026, depending on dose and pharmacy. NP Thyroid (Acella Pharmaceuticals) is a competing DTE product and sits in a similar price range, commonly $50 to $80 per month cash.

Insurance coverage for Armour Thyroid is less reliable than for generic levothyroxine. Many commercial formularies list Armour Thyroid at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), translating to copays of $35 to $80 even for insured patients. Some Medicare Part D plans exclude DTE products entirely or require step therapy with generic levothyroxine first.

The evidence base for DTE versus levothyroxine monotherapy remains limited. A randomized crossover trial published in the Journal of Clinical Endocrinology and Metabolism (N=70) found that 49% of patients preferred DTE over levothyroxine monotherapy after 16 weeks on each, while 19% preferred levothyroxine and 33% expressed no preference [6]. Body weight was modestly lower during the DTE phase (mean difference 2.6 lbs, P<0.05). The ATA notes that these findings warrant further investigation but that current evidence does not support universal first-line use of DTE over levothyroxine [7].

For cost-conscious patients already stable on DTE, the GoodRx coupon for Armour Thyroid at major chains brings the price to roughly $55 to $75 per month, which is meaningfully more than generic levothyroxine but less than many branded medications for other chronic conditions.

Compounded T3/T4: Insurance Coverage and What Compounders Charge

Compounded thyroid formulations, typically a customized ratio of T4 (levothyroxine) and T3 (liothyronine), occupy a gray zone in both clinical practice and insurance reimbursement. The combination allows prescribers to dial in exact T3:T4 ratios that are not available in commercially approved products (which offer only fixed-ratio DTE or T4-only tablets).

What compounding pharmacies charge

A 30-day supply of compounded T3/T4 at a PCAB-accredited compounding pharmacy typically runs $30 to $120, depending on:

• The specific T3:T4 ratio prescribed
• Whether slow-release (SR) liothyronine is used (adds roughly $15 to $30 per fill)
• Geographic location of the pharmacy
• Capsule count and fill volume

Slow-release T3 preparations are popular in functional medicine prescribing because commercially available liothyronine (Cytomel) has a short half-life of approximately 1 day, producing T3 peaks that some patients find symptomatic. Compounded SR T3 attempts to blunt that peak. No FDA-approved SR liothyronine exists, a fact the FDA has noted when issuing guidance on compounding [8].

Insurance coverage: the short answer is usually no

Most commercial insurance plans do not cover compounded medications unless a commercially available equivalent does not exist. Because both levothyroxine and liothyronine are available as FDA-approved products, insurers typically deny coverage for compounded T3/T4 combinations on the grounds that commercially approved alternatives exist. Patients who want a custom T3:T4 ratio generally pay entirely out of pocket.

Medicare Part D explicitly excludes compounded medications made from bulk drug substances unless those substances appear on the FDA's 503B outsourcing facility list or the medication meets specific criteria under Section 503A of the Federal Food, Drug, and Cosmetic Act [9]. Compounded thyroid formulations rarely qualify under Part D, so Medicare patients face full out-of-pocket cost.

Some health savings account (HSA) and flexible spending account (FSA) funds can be used to pay for compounded medications prescribed by a licensed provider, which at least provides a pre-tax benefit for patients committed to this approach.

How to Pay Less: Manufacturer Savings Programs and Discount Strategies

Whether a patient is on generic levothyroxine, Synthroid, Tirosint, or Armour Thyroid, several cost-reduction tools are available. The right combination depends on insurance status, Medicare/Medicaid eligibility, and the specific product prescribed.

For commercially insured patients

AbbVie Synthroid Savings Card. Eligible patients pay as little as $0 per month (up to program limits). Enrollment is at SynthroidSavings.com. The card cannot be used by patients on federal healthcare programs.

Tirosint MyWay Savings. Eligible patients pay $0 to $15 per fill. Prior authorization approval is usually required before the savings card reduces cost at the pharmacy.

Armour Thyroid. AbbVie does not currently operate a dedicated copay card for Armour Thyroid. GoodRx, RxSaver, and NeedyMeds coupons provide the most accessible discounts, bringing cash price to roughly $55 to $75 per month.

For uninsured or underinsured patients

GoodRx and similar platforms function by negotiating rates with pharmacy benefit managers. For generic levothyroxine, GoodRx rarely adds value over already-cheap $4 programs at Walmart or Costco. For Synthroid or Tirosint, GoodRx coupons can shave $30 to $80 off cash price but will not match savings-card pricing for eligible insured patients.

NeedyMeds.org maintains a database of patient assistance programs. AbbVie's patient assistance program (myAbbVie Assist) may offer free Synthroid to patients who meet income eligibility criteria, typically below 400% of the federal poverty level and without prescription drug coverage.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic levothyroxine at approximately $5 for 90 tablets (100 mcg) as of early 2026, which is one of the lowest available prices without insurance [10].

90-day supply vs. 30-day supply

Ordering a 90-day supply at a mail-order or preferred pharmacy almost always reduces per-pill cost. For generic levothyroxine, a 90-day supply at Costco or Walmart typically costs $9 to $12, compared to $4 to $10 for 30 tablets. The savings are modest in absolute terms for levothyroxine, but consistent refill behavior also reduces the risk of accidental gaps in therapy, which can affect TSH stability.

Insurance and Prior Authorization: What Triggers a Denial

Generic levothyroxine almost never triggers a prior authorization (PA) request. Brand-name Synthroid may require PA at some plans; the standard question is whether the patient has tried and failed generic levothyroxine. Most PA approvals for Synthroid require documentation of documented TSH variability on at least two different generic lots or a specific clinical reason such as difficulty swallowing tablets.

Tirosint PA requirements are more rigorous. Typical criteria include:

• Documented malabsorption syndrome (celiac disease, short bowel, Whipple's disease) or
• Concurrent use of a medication known to reduce levothyroxine absorption (omeprazole, ferrous sulfate, calcium carbonate, sucralfate) where dose adjustments have failed to stabilize TSH, or
• Patient inability to swallow tablets (pediatric, dysphagia)

Armour Thyroid PA, when required, typically demands a trial of generic levothyroxine with inadequate clinical response despite TSH normalization, plus a clinical note documenting the prescriber's rationale for DTE.

Denials can be appealed. A peer-to-peer review between the prescribing endocrinologist and the plan's medical director resolves a meaningful proportion of initial denials. If the appeal fails, patients can request a formulary exception citing medical necessity under ACA provisions [11].

Liothyronine (Cytomel) as an Add-On: Separate Cost Considerations

Some patients on levothyroxine monotherapy who continue to report symptoms despite normal TSH are prescribed add-on liothyronine (Cytomel, T3). A 2019 meta-analysis of 14 randomized controlled trials published in Thyroid (N=1,216) found no consistent benefit of combination T4/T3 therapy over T4 monotherapy on quality-of-life, mood, or cognitive measures when evaluated at standard doses [12]. The AACE/ATA guidelines note that combination therapy may be appropriate for a subgroup of patients but stop short of recommending it broadly.

On the cost side, generic liothyronine (5 mcg or 25 mcg tablets) costs approximately $30 to $60 per month cash at most pharmacies. GoodRx discounts generic liothyronine to roughly $18 to $40 at major chains. Brand-name Cytomel's list price exceeds $200 per month; few patients pay that amount given generic availability.

A patient on generic levothyroxine plus generic liothyronine could pay as little as $20 to $40 combined per month at a $4-generic-program pharmacy, making this combination affordable even without insurance.

Medicare Part D Coverage for Thyroid Medications in 2026

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D took full effect in 2025 and continues through 2026. For most thyroid medications, this cap matters primarily for patients with multiple expensive medications, because generic levothyroxine costs so little that it rarely strains the Part D budget on its own.

Under the 2026 standard Part D benefit design:

• Generic levothyroxine: Tier 1 at most plans; $0 to $3 per fill at preferred network pharmacies.
• Synthroid: Tier 2 or Tier 3 at most plans; copay typically $15 to $47 per fill. Manufacturer copay cards cannot be used with Part D.
• Armour Thyroid/NP Thyroid: Tier 3 to Tier 4 at most plans; copay $35 to $80 per fill if covered; some plans exclude entirely.
• Tirosint: Non-preferred brand or excluded at many plans; if covered, copay typically $45 to $100 per fill.
• Compounded T3/T4: Generally not covered.

Patients comparing Part D plans during open enrollment should use the Medicare Plan Finder (medicare.gov/plan-compare) and input their specific levothyroxine dose and any additional thyroid medications to get actual formulary cost estimates, not just the monthly premium.

When the Cheapest Option Is Not the Right Option: Clinical Context

The $4 generic is appropriate for most patients with uncomplicated hypothyroidism who have been stable on a particular levothyroxine formulation. Switching manufacturers, even between two approved generics, can shift serum TSH by a clinically meaningful margin in some patients due to minor differences in excipient composition or tablet disintegration characteristics.

A study published in JAMA Internal Medicine (N=14,234 thyroid cancer patients on TSH-suppressive therapy) found that patients who experienced manufacturer switches had a 12% higher rate of TSH out-of-range values in the 6 months following the switch compared to those who remained on the same manufacturer's product [13]. TSH suppression targets in thyroid cancer patients are far tighter (TSH <0.1 mIU/L for high-risk patients) than in routine hypothyroidism, so this finding may not apply equally to patients with benign disease, but it illustrates why stability of supply matters.

For most stable, benign hypothyroid patients, the AACE/ATA guideline recommendation is reasonable: choose one formulation, fill consistently at the same pharmacy chain to minimize manufacturer variability, and recheck TSH six weeks after any forced switch [2]. The cheapest option that can be filled consistently at a preferred pharmacy is usually the right choice.